Lates News

According to a research report released by Open Source Securities on December 15th, Zhejiang Jingxin Pharmaceutical Co., Ltd. (300181.SZ) was given a "buy" rating. The rating reasons mainly include: 1) the market space for various trace element injection liquids is large, and the identity of "medical insurance + centralized procurement" helps to increase sales; 2) rich product structure, marketing synergy development. (Daily Economic News)